SCHEMBL6768693

SCHEMBL6768693

N#Cc1cc(-c2cccs2)c(-c2ccco2)nc1N

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 11/20 0.63
ADORA1 P30542 10/20 0.63
ADORA2B P29275 7/20 0.63
PIM1 P11309 1/20 0.50
TOP1 P11387 1/20 0.49
ALDH1A1 P00352 3/20 0.44
KDM4E B2RXH2 2/20 0.44
HPGD P15428 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
NPC1 O15118 1/20 0.44
RAB9A P51151 1/20 0.44
HSD17B10 Q99714 1/20 0.44
POLB P06746 2/20 0.42
GAA P10253 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
HCRTR1 O43613 1/20 0.41
GLA P06280 1/20 0.41
CSNK2A1 P68400 1/20 0.41
F2 P00734 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6775433 0.85 ADORA2A (0.56) ADORA2AADORA1ADORA2BALDH1A1KDM4E
SCHEMBL6768606 0.83 ADORA2A (0.48) ADORA2AADORA1ADORA2BALDH1A1KDM4E
SCHEMBL6769341 0.82 ADORA2A (0.45) ADORA2AADORA1ADORA2BALDH1A1KDM4E
SCHEMBL6768974 0.81 ADORA2A (0.44) ADORA2AADORA1ADORA2BALDH1A1KDM4E
SCHEMBL6765605 0.81 ADORA2A (0.46) ADORA2AADORA1ADORA2BALDH1A1KDM4E
SCHEMBL3840501 0.81 PIK3R1 (0.49) ADORA2AADORA1ADORA2BALDH1A1KDM4E
SCHEMBL6770469 0.81 PIK3R1 (0.54) ADORA2AADORA1ADORA2BALDH1A1KDM4E
SCHEMBL6768976 0.80 ADORA2A (0.60) ADORA2AADORA1ADORA2BALDH1A1KDM4E
SCHEMBL6768967 0.79 ADORA2A (0.44) ADORA2AADORA1ADORA2BALDH1A1KDM4E
SCHEMBL6768956 0.78 ADORA2A (0.46) ADORA2AADORA1ADORA2BALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6750232-B2 ADENOSINE ANTAGONIST; AN IMPORTANT REGULATORY FACTOR INVOLVED IN VARIOUS INTRACELLULAR METABOLISMS SUCH AS REGULATION OF ENERGY LEVELS EISAI CO., LTD. (JP) 2004-06-15 US disclosed
US-20040006082-A1 2-Aminopyridine compounds and use thereof as drugs EISAI R&D MANAGEMENT CO., LTD. (JP) 2004-01-08 US disclosed
EP-1308441-A1 2-AMINOPYRIDINE COMPOUNDS AND USE THEREOF AS DRUGS Eisai Co., Ltd. (JP) 2003-05-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006082-A1 2-Aminopyridine compounds and use thereof as drugs ADORA1, ADORA2B, ADORA2A ADORA2A 3/4885ADORA1 1/4885ADORA2B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.